Leveraging metabolic restriction in cooperation with SHP2 deficiency to inhibit PDAC (AACRPanCa 2026) - Oct 15, 2026 - Abstract #A118; "We compared SHP2i/KO to MEK inhibition (Trametinib) by extracellular flux assays to differentiate metabolic responses. SHP2 is overexpressed (PAAD-TCGA vs GTEx), overabundant (CPTAC proteomic data), and active (pY542/Y580; CPTAC/immunohistochemistry) in PDAC versus normal pancreas tissue. Inhibition of SHP2 with SHP099 (SHP2i) reduced in vitro proliferation in both murine KPC or human PDAC cell lines. Interestingly, the anti-proliferative effects of SHP2i were time dependent and correlated with media acidification."
Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS • PTPN11
|
|
McKinnon Walsh; Austin Eades; Bailey Bye; Mariana Ruckert; Joseph Cesare; Dennis Province; Collin McCoin; John Thyfault; Michael Washburn; Stephanie Byrum; Michael VanSaun
|